Molecular Partners Shareholders Equity (Quarterly) Analysis

Molecular Partners AG (MOLN)

4.39 +0.41 (+10.30%) USD | NASDAQ | May 06, 15:55

Shareholders Equity (Quarterly) Chart

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	210.05M
September 30, 2023	214.45M
June 30, 2023	229.05M
March 31, 2023	243.20M
December 31, 2022	253.65M
September 30, 2022	257.84M
June 30, 2022	278.59M
March 31, 2022	286.48M
December 31, 2021	117.37M
September 30, 2021	133.15M
June 30, 2021	146.19M
December 31, 2020	122.72M
June 30, 2020	32.60M
December 31, 2019	55.88M
June 30, 2019	79.92M

Date	Value
June 30, 2019	79.92M
December 31, 2018	93.14M
June 30, 2018	116.61M
June 30, 2018	116.61M
December 31, 2017	119.83M
June 30, 2017	123.79M
June 30, 2017	123.79M
December 31, 2016	133.45M
June 30, 2016	144.36M
June 30, 2016	144.36M
December 31, 2015	153.57M
June 30, 2015	154.35M
June 30, 2015	154.35M
December 31, 2014	150.16M

Shareholders' Equity Definition

Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

32.60M

Minimum

Jun 2020

286.48M

Maximum

Mar 2022

171.32M

Average

178.12M

Median

Shareholders Equity (Quarterly) Benchmarks

AC Immune SA	191.25M
CRISPR Therapeutics AG	1.883B
Addex Therapeutics Ltd	1.364M
NLS Pharmaceutics Ltd	-4.287M
MoonLake Immunotherapeutics	495.68M

Shareholders Equity (Quarterly) Related Metrics

Total Assets (Quarterly)	236.15M
Total Liabilities (Quarterly)	26.10M
Current Ratio	13.35